Abstract

iPSC-derived neurons are providing human cellular models for hitherto inaccessible tissues. However, these neuronal models are not without their problems, including cellular heterogeneity, consistency and maturity. I will show how we are facing these problems with dopaminergic models for Parkinson's disease. Firstly, I will show how we can validate these neuronal models for drug discovery. Secondly, I will show how we can apply single cell pseudotemporal ordering approaches to these models to reveal the evolving disease-associated perturbations and identify new targets for Parkinson's therapeutics.